Mersana Therapeutics Inc expected to post a loss of $3.93 a share - Earnings Preview

Mersana Therapeutics

08/08/2025 16:31

Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2025

The Cambridge Massachusetts-based  company is expected to report a 177.5% increase in revenue to $6.363 million from $2.29 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Mersana Therapeutics Inc is for a loss of $3.93 per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mersana Therapeutics Inc is $137.50, about 95.2% above its last closing price of $6.61

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-4.52
-4.85
-4.75
Beat
2.1
Dec. 31 2025
-4.04
-4.03
-2.75
Beat
31.7
Sep. 30 2024
-4.38
-4.39
-2.25
Beat
48.7​
Jun. 30 2024
-4.28
-4.29
-5.00
Missed
-16.7
​​Mar. 31 2024
-4.38
-4.52
-4.00
Beat
11.6
Dec. 31 2023
-3.03
-4.11
-4.00
Beat
2.6​
Sep. 30 2023
-8.78
-9.05
-6.75
Beat
25.4
Jun. 30 2023
-9.34
-11.04
-11.75
Missed
-6.5

This summary was machine generated August 8 at 15:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)